WP
ASMB icon

Woodline Partners’s Assembly Biosciences ASMB Stock Holding History

Woodline Partners’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.14M Buy
+150,780
New +$4.1M 0.01% 731

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Woodline Partners's ASMB Position: Q2 2026 in Review

Woodline Partners opened a new position in Assembly Biosciences (ASMB) in Q2 2026: 150,780 shares worth $4.14M. The stake represents 0.01% of the portfolio and ranks #731 among its holdings.

93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Woodline Partners held 150,780 shares of Assembly Biosciences worth $4.14M as of Q2 2026.
  • Assembly Biosciences was a new Woodline Partners position in Q2 2026.
  • Assembly Biosciences made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #731 holding.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.